My ePortfolio Register   

Mechanisms of resistance to CDK4/6 inhibitors in triple negative breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.05.17
Views: 774

Dr Uzma Asghar - The Institute of Cancer Research, London, UK

Dr Asghar speaks with ecancer at IMPAKT 2017 about the use of CDK inhibitors against triple negative breast cancer.

She highlights the luminal androgen receptor subtype as especially sensitive, in introduces upcoming trials of combined CDK/PI3K targeted therapies. 

CDK inhibitors have been discussed in ecancer sessions at the St. Gallen 2017 conference, at EONS 10, and at ESMO 2016

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence